...
首页> 外文期刊>Parkinsonism & related disorders >123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis
【24h】

123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis

机译:123I-MIBG心肌显像技术将帕金森氏病与其他神经退行性帕金森病区分开来:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例

摘要

Objectives: Differential diagnosis of Parkinson's disease (PD) and other neurodegenerative parkinsonism by clinical consensus criteria and diagnostic imaging is often difficult. 123I-meta-iodobenzylguanidine ( 123I-MIBG) myocardial scintigraphy is a useful imaging tool for differentiating PD from other parkinsonism. The purpose of the present study is to systematically review and perform a meta-analysis of studies on the diagnostic performance of 123I-MIBG myocardial scintigraphy for the differential diagnosis of PD and other neurodegenerative parkinsonism, specifically multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Methods: A computer literature search of the PubMED/MEDLINE database was conducted to find relevant published articles on 123I-MIBG myocardial scintigraphy for the differential diagnosis of PD and other neurodegenerative parkinsonism. We used the bivariate random-effects model to obtain the pooled estimates of the sensitivity and specificity and the corresponding 95% confidence intervals. Results: Thirteen studies comprising 845 patients including 625 PD and 220 other neurodegenerative parkinsonism were analyzed. The pooled sensitivity and specificity to differentiate PD from other neurodegenerative parkinsonism by the early heart-to-mediastinum (H/M) ratio were 82.6% and 89.2%, respectively, and those by the delayed H/M ratio were 89.7% and 82.6%, respectively. When PD was limited to early stage (Hoehn-Yahr stage 1 or 2), the pooled sensitivity and specificity by the delayed H/M ratio were 94.1% and 80.2%, respectively. Conclusions: The present meta-analysis confirmed high sensitivity and specificity of 123I-MIBG myocardial scintigraphy for differentiating PD from other neurodegenerative parkinsonism in both early and delayed imaging phases. Furthermore, 123I-MIBG myocardial scintigraphy was highly effective for distinguishing early PD.
机译:目的:通过临床共识标准对帕金森氏病(PD)和其他神经退行性帕金森病进行鉴别诊断,通常难以诊断。 123I-间碘碘苄基胍(123I-MIBG)心肌闪烁显像术是区分PD与其他帕金森病的有用影像学工具。本研究的目的是系统地回顾和分析关于123I-MIBG心肌闪烁显像对PD和其他神经退行性帕金森病(特别是多系统萎缩,进行性核上性麻痹和皮质基底膜)的鉴别诊断的研究结果的荟萃分析。退化。方法:对PubMED / MEDLINE数据库进行计算机文献检索,以找到有关123I-MIBG心肌闪烁显像的相关已发表文章,以鉴别诊断PD和其他神经变性帕金森病。我们使用双变量随机效应模型来获得敏感性和特异性以及相应的95%置信区间的合并估计。结果:分析了包括845例625例PD和220例其他神经变性帕金森病在内的845例患者的13项研究。通过早期心脏/纵隔(H / M)比率将PD与其他神经退行性帕金森病区分开来的综合敏感性和特异性分别为82.6%和89.2%,而通过延迟​​H / M比率获得的敏感性和特异性分别为89.7%和82.6% , 分别。当PD局限于早期阶段(Hoehn-Yahr阶段1或2)时,通过延迟H / M比合并的敏感性和特异性分别为94.1%和80.2%。结论:目前的荟萃分析证实了123I-MIBG心肌闪烁显像技术在早期和延迟成像阶段可将PD与其他神经变性帕金森病区分开来的敏感性和特异性。此外,123I-MIBG心肌显像对区分早期PD非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号